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Toll-like receptor 4 and protease-activated receptor 2 
in physiology and pathophysiology of the nervous 
system: more than just receptor cooperation?
Controversial Roles of Toll-Like Receptor 4  
and Protease-Activated Receptor 2 in 
Neurodegenerative Disorders 
Toll-like receptor 4 (TLR4) and protease-activated receptor 
2 (PAR2) are expressed in neuronal and glial cells and are 
involved in development and progression of neurodegen-
erative diseases with an inflammatory component. Notably, 
depending on the context, both receptors can have either 
neuroprotective roles or contribute to neurodegeneration. 
This correlates with the intrinsic ability of PAR2 and TLR4 
to mediate both pro- and anti-inflammation. 
In this respect, neuronal activation of PAR2 has been 
shown to protect against neuroinflammation and Amyloid β 
neurotoxicity in mouse models of Alzheimer’s disease (AD) 
(Afkhami-Goli et al., 2007). On the other hand, activation 
of PAR2 in microglia leads to increased production and 
secretion of inflammatory mediators contributing to the on-
going neurodegeneration [(reviewed in Ramachandran et al. 
(2012)]. Overall, PAR2 activation in AD can have either neu-
roprotective or neurodegenerative effects depending on the 
cell type and the stage of disease progression (Afkhami-Goli 
et al., 2007). Similarly, the role of TLR4 in AD is not well 
understood. We and others have demonstrated that amyloid 
β activates TLR4, induces neuroinflammation, and thereby 
drives neuronal apoptosis (Tang et al., 2008; Zeuner et al., 
2017). In contrast, activation of TLR4 with a detoxified moi-
ety of Salmonella minnesota-derived lipopolysaccharide has 
been demonstrated to reduce the levels of neuroinflammation 
and improve AD-related pathology in vivo (Michaud et al., 
2013). In a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat 
model of Parkinson’s disease (PD) (another neurodegener-
ative disease with a strong link to ongoing neuroinflamma-
tion), PAR2 blockade has been shown to reduce the levels of 
α-synuclein and the pro-inflammatory cytokines interleu-
kin-1 beta and tumor necrosis factor-alpha in the substantia 
nigra, suggesting a pro-inflammatory role of the receptor. 
Of note, in addition to the reduction of neuroinflammation, 
antagonism of PAR2 reversed behavioural deficits (Liu et al., 
2014). However, more recent reports studying post mortem 
brain tissue of patients with PD, demonstrated altered ex-
pression levels of both, PAR2-activator serine proteases and 
serine protease inhibitors (Hurley et al., 2015) making the 
role of PAR2 in PD less clear. In this context, TLR4 has been 
shown to promote neuronal cell death in the 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine model of PD (Noelker et al., 
2013). However, TLR4 has also been shown to mediate the 
clearance of extracellular α-synuclein deposits by microglia 
and TLR4 ablation increased the progressive loss of dopami-
nergic neurons and the resultant motor disability (reviewed in 
Trotta et al. (2014)). We have performed a detailed PubMed 
literature analysis on the current knowledge on the coopera-
tion and potential cross-coupling between TLR4 and PAR2.
Signaling via Toll-Like Receptor 4 
TLR4 is a pattern recognition receptor and a member of the 
toll-like receptor (TLR) family. TLRs are involved in non-
specific immune responses via recognition of Gram-positive 
and Gram-negative bacteria, DNA, RNA viruses, fungi, 
and protozoa (pathogen-associated molecular pattern) with 
bacterial lipopolysaccharides (LPSs) acting as specific patho-
gen-associated molecular patterns for TLR4. 
In addition to their respective specific pathogen-associat-
ed molecular patterns, TLRs recognise endogenous signals 
of cell death and tissue damage (danger-associated molecu-
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Toll-like receptor 4 (TLR4) and protease-activated receptor 2 (PAR2) play pivotal roles in the mammalian 
innate immune response. Notably, in addition to their involvement in detection of invading pathogens, 
PAR2 and TLR4 modulate the levels of cell death-induced sterile inflammation by activating pro- or an-
ti-inflammatory downstream signaling cascades. Within the central nervous system, there is emerging 
evidence that both receptors are involved in synaptic transmission and brain plasticity. Furthermore, due 
to their prominent role in mediating neuroinflammation, PAR2 and TLR4 are associated with development 
and progression of neurodegenerative disorders including but not limited to Alzheimer’s disease, Parkin-
son’s disease and multiple sclerosis. In this article, we summarise the current knowledge on the cooperation 
between PAR2 and TLR4, discuss the potential cross-talk levels and highlight the impact of the cross-cou-
pling on neuroinflammation.
Key Words: signaling; inflammation; proteases; myeloid of differentiation primary response gene 88; TIR-domain 
containing adaptor inducing interferon; lipopolysaccharide; TLR4; PAR2
REVIEW
*Correspondence to:
Darius Widera, PhD,
d.widera@reading.ac.uk.
#These authors contributed 
equally to this work.
orcid: 
0000-0003-1686-130X 
(Darius Widera)
0000-0001-9098-7627 
(Graeme S. Cottrell)
doi: 10.4103/1673-5374.251290
Received: December 12, 2018
Accepted: January 14, 2019
Darius Widera1, *, #, Rocío Martínez Aguilar1, 2, Graeme S. Cottrell3, #
1 Stem Cell Biology and Regenerative Medicine Group, School of Pharmacy, University of Reading, Whiteknights campus, Reading, UK
2 Unidad de Inmunología, IBIMER, Universidad de Granada, Granada, Spain
3 Cellular and Molecular Neuroscience, School of Pharmacy, University of Reading, Reading, UK
[Downloaded free from http://www.nrronline.org on Thursday, May 30, 2019, IP: 134.225.109.120]
1197
Widera D, Martínez Aguilar R, Cottrell GS (2019) Toll-like receptor 4 and protease-activated receptor 2 in physiology and pathophysiology of 
the nervous system: more than just receptor cooperation? Neural Regen Res 14(7):1196-1201. doi:10.4103/1673-5374.251290
lar patterns), thereby driving sterile inflammation. 
At the molecular level, binding of different LPS chemo-
types or endogenous protein ligands to TLR4 can activate 
the prototypic pro-inflammatory transcription factor nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-
κB), the antiviral and anti-inflammatory transcription factor 
interferon regulatory transcription factor 3 (IRF3) and the 
kinases c-Jun N-terminal kinase and extracellular-regulated 
protein kinases (ERKs). Importantly, all LPS chemotypes 
and danger-associated molecular patterns described to date 
activate NF-κB and IRF3, whereas ERK and c-Jun N-terminal 
kinase are only influenced by certain ligands (Palsson-Mc-
Dermott and O’Neill, 2004). In this context, the balance 
between the levels of NF-κB and IRF3 activation depends on 
the nature of the ligand and can at least partly be attributed 
to the biased agonism via TLR4 (Zeuner et al., 2016). 
LPS is transported to TLR4 by LPS-binding protein and 
depending on the cell type, soluble or membrane bound 
CD14 is then recruited to this complex (Figure 1A) (Hailman 
et al., 1994). In the presence of LPS, myeloid of differentia-
tion protein 2 forms a heterotetramer with TLR4 and regu-
lates the responsiveness to different LPS chemotypes (Casella 
and Mitchell, 2013). If the TLR4 complex internalises by en-
docytosis, it activates mainly IRF3. In contrast, plasma mem-
brane initiated TLR4 signaling promotes NF-κB activation. 
In addition to the subcellular localisation, TLR4 down-
stream signaling depends on the adapter molecule recruited 
to the intracellular Toll/interleukin-1 receptor (TIR)-do-
main of TLR4. The recruited adaptor proteins are either 
the myeloid of differentiation primary response gene 88 
(MyD88) or the TIR-domain containing adaptor inducing 
interferon (TRIF). Thus, signaling downstream of TLR4 
can be either MyD88-dependent or MyD88-independent. 
TRIF and TRIF-related adapter molecule (TRAM) initiate 
activation of tumour necrosis factor receptor-associated fac-
tor (TRAF)3 (Fitzgerald et al., 2003). Further downstream, 
TRAF family member associated NF-κB activator-binding 
kinase 1 associates with the inhibitor of κB (IκB) kinase 
(IKK)ε to phosphorylate the transcription factor interferon 
regulatory factor (IRF)3 promoting its nuclear translocation 
(Fitzgerald et al., 2003). Phosphorylated and thus activated 
IRF3 has both anti-viral and anti-apoptotic properties and is 
considered anti-inflammatory (Tarassishin et al., 2013). 
In contrast, recruitment of MyD88 to the TIR-domain of 
TLR4 at the plasma membrane initiates the formation of the 
so called Myddosome containing MyD88, MyD88 adapter 
like (Mal or TIR-domain adapter protein) and interleukin-1 
receptor-associated kinase 1/2 and 4 (Dossang et al., 2016). 
This protein complex promotes further downstream signal-
ing, eventually activating the IKK complex. The IKK com-
plex is composed of the catalytic subunits IKKα and β, and 
the regulatory subunit NF-κB essential modulator (NEMO, 
also referred to as IKKγ). Activated IKKβ phosphorylates 
the IκBα, in turn leading to its polyubiqitination and prote-
asomal degradation. As a cytosolic inhibitor protein, IκBα 
masks the nuclear localisation signal of the pro-inflamma-
tory transcription factor NF-κB. Thus, its proteasomal deg-
radation frees NF-κB and allows its nuclear translocation. 
Subsequently, NF-κB binds to its consensus sequences and 
positively modulates the transcription of its pro-inflamma-
tory target genes (e.g., tumor necrosis factor-alpha) (Kawai 
and Akira, 2007). 
Importantly, TLR4 signaling is tremendously sensitive to 
the nature, purity and concentration of the ligand and other 
parameters. Specifically, common technical and conceptual 
pitfalls in studying TLR4 signaling include the use ligands 
of unspecified chemotype and purity, inappropriate culture 
conditions (e.g., serum-free medium for cells lacking CD14) 
or the choice of inappropriate cellular model (e.g., unmodi-
fied human embryonic kidney (HEK) cells for the that lack 
adapters required to fully activate the MyD88-independent 
signaling) (Zeuner et al., 2015). 
Protease-Activated Receptor 2 Signaling
PAR2 is a member of a small family of G protein-coupled 
receptors that are activated by an ever-growing repertoire of 
proteases. Activating proteases cleave PAR2 within its N-ter-
minus to create a new N-terminus that binds to and activates 
the receptor (reviewed in Ossovskaya and Bunnett (2004)). 
Once activated PAR2 couples to Gαq proteins to promote the 
mobilization of intracellular Ca2+ and there are also reports of 
PAR2-dependent cyclic adenosine monophosphate (cAMP) 
accumulation, presumably via Gαs proteins (Figure 1B). In 
addition to G protein-dependent signaling cascades, similar 
to other G protein-coupled receptors, PAR2 also activates 
mitogenic signaling pathways. Extracellular-regulated pro-
tein kinases are activated via cell surface-dependent signaling 
molecules and also from internalized PAR2 in endosomes 
(DeFea et al., 2000). In common with TLR4, PAR2 activates 
the pro-inflammatory NF-κB signaling cascade. PAR2-de-
pendent activation of NF-κB has been reported in bovine cor-
onary artery smooth muscle cells (Bretschneider et al., 1999), 
human dermal microvascular endothelial cells (Buddenkotte 
et al., 2005) and keratinocytes (Macfarlane et al., 2005).
As with other GPCRs, it is now clear that different ago-
nists of PAR2 can activate distinct signaling pathways or 
activate the same pathways in a biased manner (reviewed in 
Hollenberg et al. (2014) and Zhao et al. (2014a)). For exam-
ple, trypsin activates human PAR2 revealing a new N-ter-
minus of S37LIGKV (Knecht et al., 2007), whereas human 
neutrophil elastase cleaves PAR2 creating a new N-terminus 
of V68LTGKL (Ramachandran et al., 2011). These unique 
intra-molecular ligands activate diverse signaling pathways, 
with trypsin promoting both Gαq-coupling and ERK1/2 ac-
tivation, whereas neutrophil elastase only activates ERK1/2 
(Ramachandran et al., 2011). Another neutrophil-derived 
protease, cathepsin G cleaves PAR2 in yet another position 
of its N-terminus, but no known signaling cascades have yet 
been elucidated following this cleavage and thus, cathepsin 
G is currently considered as a disabling PAR2 protease (Ra-
machandran et al., 2011). Synthetic peptides that mimic the 
proteolytically-derived N-terminus are widely used as specif-
ic pharmacological tools to activate PARs. However, it is also 
clear that these are also biased agonists (Ramachandran et 
al., 2009) and thus, nothing truly recapitulates the activation 
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via proteases and care must be taken when interpreting the 
observations when using these tools both in vitro and in vivo.
As well as differences in signaling cascades, biased ago-
nists of PAR2 have major differences in the agonist-induced 
trafficking of the receptor. Trypsin-dependent cleavage of 
PAR2 promotes dynamin-, clathrin- and β-arrestin-depen-
dent internalization to endosomes and ultimately ubiqui-
tin-dependent downregulation of the receptor in lysosomes 
(Bohm et al., 1996; Dery et al., 1999; Roosterman et al., 2003; 
Jacob et al., 2005). In stark contrast, PAR2 remains on the 
cell surface following cleavage with neutrophil elastase and 
cathepsin S (Zhao et al., 2014b, 2015). As receptor signal-
ing is intimately linked to receptor trafficking (reviewed in 
Villasenor et al. (2016)), indeed signaling from endosomes 
clearly has different properties to that elicited from the cell 
surface, it is important that we not only define the biased 
signaling pathways, but also how they relate to biased traf-
ficking of receptors. Only then can we define new therapeu-
tic targets and interventions.
Bacteria secrete many proteases, but there have been sur-
prisingly few reports of direct cleavage of PARs by bacterial 
proteases. Pseudomonas aeruginosa elastase cleaves PAR2, 
but does not promote internalization, leaving PAR2 at the 
plasma membrane. Furthermore, intracellular Ca2+ release 
was not promoted (Dulon et al., 2005). A protease from 
Group A Streptococcus, a cysteine protease streptococcal 
pyrogenic exotoxin B was similarly found to disarm PAR1, 
preventing thrombin-induced ERK1/2 activation and plate-
let aggregation (Ender et al., 2013). The only reported acti-
vator of PAR2 is gingipain-R derived from Porphyromonas 
gingivalis (Lourbakos et al., 1998). Challenge of human neu-
trophils with purified gingipain-R, promoted intracellular 
Ca2+ mobilization in a PAR2-dependent mechanism. Given 
the large number of potential activating and disabling prote-
ases secreted by invading bacteria and other pathogens, this 
is an area that warrants further investigation.
Potential Interaction Between Toll-Like 
Receptor 4 and Protease-Activated Receptor 2  
and Controversy on the Downstream Signaling
Although both TLR and PAR2 are expressed in the central 
nervous system and play similar roles in several brain pa-
thologies, little is known about their interaction in brain 
Figure 1 Toll-like receptor 4 (TLR4) and protease-activated receptor 2 (PAR2) signaling pathways. 
(A) Lipopolysaccharide (LPS) is transferred to TLR4 by CD14 followed by formation of TLR4/myeloid of differentiation protein 2 (MD2) heterotetramers. 
Membrane-bound TLR4 signaling complex induces the myeloid of differentiation primary response gene 88 (MyD88)-dependent signaling cascade by recruit-
ing MyD88 and tumor necrosis factor receptor associated factor (TRAF)6 which in turn activates transforming growth factor activated kinase-1 (TAK1) and 
the inhibitor of nuclear factor kappa-B kinase (IKK) complex composed of IKKα, IKKβ and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) essential modulator (NEMO). IKKβ phosphorylates inhibitory inhibitor of κB (IκB) proteins leading to their polyubiquitination and proteasomal 
degradation. This frees the DNA binding NF-κB subunits which in turn translocate into the nucleus and modulate expression of the pro-inflammatory target 
genes including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β and IL-8. In contrast, internalised, endosomal TLR4 complex recruits Toll/IL-1 re-
ceptor (TIR)-domain containing adaptor inducing interferon (TRIF) and TRIF-related adapter molecule (TRAM) activating thereby the MyD88 independent 
signaling cascade. Subsequently, TRAF3 activates the TRAF family member associated NF-κB activator (TANK)-binding kinase (TBK)1/IKKε which in turn 
phosphorylates interferon regulatory transcription factor 3 (IRF3) followed by its nuclear translocation and transcription of anti-inflammatory targets in-
cluding type I interferons and IL-10. Notably, the MyD88 independent signaling cascade also cross-activates NF-κB via interaction between TRIF/TRAM and 
TRAF6 leading to a weak and late NF- κB activation. (B) Trypsin cleaves PAR2 to expose a new N-terminus which acts as an intramolecular ligand, activating 
the receptor. Gαq-coupling promotes the mobilization of intracellular Ca2+ and production of diacylglycerol (DAG), the latter activating protein kinase C (PKC). 
Raf-1 is in turn activated by PKC. Activated PAR2 is phosphorylated increasing its affinity for cytosolic β-arrestins (β-arr), which translocate to the cell surface 
to interact with the receptor. PAR2-boundβ-arrs act as a molecular scaffold recruiting signaling molecules including rapidly accelerated fibrosarcoma-1 (raf-1), 
mitogen-activated protein kinase kinase (MEK) and extracellular-regulated protein kinases (ERK1/2) at the plasma membrane and in endosomes. Further ac-
tivation of NF-κB and IRF3 and activating peptide1 (AP1) occurs via as yet undefined mechanisms. Endosomal-activated ERK1/2 promotes AP1 activity. LBP: 
LPS-binding protein; JNK: c-Jun N-terminal kinase.
[Downloaded free from http://www.nrronline.org on Thursday, May 30, 2019, IP: 134.225.109.120]
1199
Widera D, Martínez Aguilar R, Cottrell GS (2019) Toll-like receptor 4 and protease-activated receptor 2 in physiology and pathophysiology of 
the nervous system: more than just receptor cooperation? Neural Regen Res 14(7):1196-1201. doi:10.4103/1673-5374.251290
cells. In other systems, a receptor cooperation and even a 
direct interaction has been postulated. However, the down-
stream signaling pathways mediated by the receptor coop-
eration are still controversially discussed. In particular, a 
synergistic PAR2 and TLR4-mediated nuclear translocation 
of NF-κB (assessed using an electrophoretic mobility shift 
assay) along with an increased production of the pro-inflam-
matory NF-κB target interleukin 6 have been reported in 
endothelial human umbilical vein endothelial cells exposed 
to synthetic PAR2 activating peptides (APs) and Escherichia 
coli (unspecified strain)-derived LPS of unknown purity (Chi 
et al., 2001). These results could suggest that PAR2 is coop-
Figure 2 Models for potential interaction between Toll-like receptor 4 (TLR4) and protease-activated receptor 2 (PAR2). 
(A) Direct interaction at the plasma membrane model. This model proposes that in absence of TLR4, PAR2 activates the myeloid of differentiation primary 
response gene 88 (MyD88) independent signaling culminating in expression of its anti-inflammatory target genes. However, this model is based on data 
from experiment involving synthetic activating peptides and does not consider the significant differences between membrane-initiated and endosomal 
PAP2 and TLR4 signaling (Rallabhandi et al., 2008). (B) Alternative model of direct interaction in endosomes. In this model, PAR2 and TLR4 interact in 
the plasma membrane and, after internalisation, within endosomes. Membrane bound heterooligomers of PAR2 and TLR4 signal via the MyD88-depen-
dent signaling cascade, whereas the endosomal heterooligomers activate the MyD88-independent signaling pathway. This model considers the proposed 
direct interaction between TLR4 and PAR2, recognises the differences between membrane initiated and endosomal signaling cascades and could explain the 
controversial role of the TLR4/PAR2 interaction in modulating pro- and anti-inflammation. (C) Signaling crosstalk model. PAR2 signaling cascade could 
cross-talk to the TLR4 signaling pathway through the ability of rapidly accelerated fibrosarcoma-1 (raf-1) to (cross-) activate tumor necrosis factor receptor 
associated factor 6 (TRAF6) which in turn could result in modulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity. 
On the other hand, TLR4 could cross-activate the PAR2 signaling cascade via transforming growth factor activated kinase-1 (TAK1)-mediated activation 
of extracellular-regulated protein kinases (ERK1/2) and subsequent regulation of activating peptide1 (AP1) activity. Overall, this model suggests a signaling 
crosstalk between PAR2 and TLR4-mediated signaling without a direct interaction of both receptors. LPS: Lipopolysaccharide; MEK: mitogen-activated 
protein kinase kinase; IL: interleukin; β-arr: β-arrestins; TRIF: Toll/IL-1 receptor-domain containing adaptor inducing interferon; TRAM: TRIF-relat-
ed adapter molecule; MD2: myeloid of differentiation protein 2; IRF3: interferon regulatory transcription factor 3; TNF-α: tumor necrosis factor-alpha; 
NEMO: NF-κB essential modulator; IKK: inhibitor of nuclear factor kappa-B kinase; IκB: inhibitor of κB.
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erating with the MyD88-dependent TLR4 signaling. This 
view is supported by a report by Zhou et al. (2011) where 
synergistic up-regulation of the pro-inflammatory NF-κB 
target gene interleukin-8 has been observed after co-stim-
ulation of the double positive SW620 cells with an AP and 
LPS of unspecified chemotype and purity. 
Over a decade ago, in an attempt to study a potential 
interaction between PAR2 and TLR4, Rallabhandi and 
colleagues used TLR4/MD-2/CD14-transduced and PAR2 
overexpressing HEK293T (endogenously negative for 
TLR4, myeloid of differentiation protein 2, and CD14) 
(Rallabhandi et al., 2008). In their study, they demonstrated 
that in the absence of TLR4, PAR2-induced NF-κB activa-
tion was inhibited by dominant negative TRIF and TRAM 
constructs. Notably, no NF-κB inhibition was seen if dom-
inant negative MyD88 constructs were used. In presence 
of TLR4, PAR2 AP showed a synergistic increase of NF-κB 
activity that was MyD88 dependent in both, TLR4/MD-2/
CD14-transduced and PAR2 overexpressing HEK293T and 
double positive SW620 colonic epithelial cells. In this study, 
PAR2 APs showed no direct TLR4 agonist activity. Con-
trol experiments in macrophages derived from TLR4–/– and 
PAR2–/– mice revealed that PAR2 APs lead to lower levels 
of interleukin-1 beta mRNA in TLR4–/– cells, while PAR2–/– 
macrophages have reduced ability to produce the TLR4 
downstream target inducible nitric oxide synthase. Interest-
ingly both activation of interleukin-1 beta and inducible ni-
tric oxide synthase are known to require MyD88-dependent 
signaling axis of TLR4 downstream cascade. 
Finally, using co-immunoprecipitation, Rallabhandi et al. 
suggested a direct association between TLR4 and PAR2. How-
ever, as the claim of direct interaction (Figure 2A) has been 
made based on co-immunoprecipitation alone, a non-direct 
interaction with involvement of intermediate adapter pro-
teins (e.g., MyD88, TRIF or TRAM) cannot be excluded. In 
order to address this open question, other modern methodical 
approaches including but not limited to proximity ligation 
assays, two-colour super-resolution microscopy, split-yellow 
fluorescent protein, fluorescence recovery after photobleaching 
or fluorescence lifetime imaging are required. Moreover, this 
study utilised lab-made phenol/water-extracted Escherichia coli 
K235-derived LPS without information on the purity potential-
ly biasing the results by co-stimulation of other receptors. 
Conversely, the same group reported that in peritoneal 
macrophages isolated from C57BL/6J mice exposed to PAR2 
APs and lab-purified LPS from E. coli K235 (no data on puri-
ty provided), an upregulation of the anti-inflammatory IRF3 
target gene interleukin-10 and suppression of the pro-inflam-
matory tumor necrosis factor-alpha, interleukin-6, and in-
terleukin-12 has been reported (Nhu et al., 2012). In general 
accordance with these findings Liang et al. reported in 2015, 
that PAR2–/– mice showed reduced levels of IRF target gene 
activation after an in vivo challenge with E. coli O55:B LPS 
of unspecified purity (Liang et al., 2015). Similarly, PAR2–/– 
mice displayed more severe lung inflammation in response to 
P. aeruginosa infection compared to wild-type animals and 
showed higher levels of the NF-κB target gene tumor necrosis 
factor-alpha (Moraes et al., 2008). These results support the 
hypothesis that PAR2 is positively modulating the MyD88-in-
dependent signaling axis of the TLR4 signaling cascade and 
thus plays an anti-inflammatory role. 
Summary and Conclusions
As emphasized above, there is increasing evidence that both 
TLR4 and PAR2 play a significant role in modulating neu-
roinflammation in health and disease of the central nervous 
system. Importantly, both receptors can activate pro- and 
anti-inflammatory signaling pathways and can have either 
neuroprotective or neurodegenerative roles. Thus, both ag-
onism and antagonism of TLR4 and PAR2 have therapeutic 
potential when targeting inflammatory diseases of the brain. 
Due to the reciprocal modulation of both receptors, devel-
oping compounds that modulate receptor interactions and 
selectively activate beneficial signaling pathway represents a 
promising strategy for targeting neurodegenerative disorders 
with an inflammatory component including but not limited 
to AD and PD. However, the exact nature of the interaction 
between PAR2 and TLR4 is still a matter of an ongoing sci-
entific debate. In particular, open questions include if the 
reciprocal signaling cross-talk occurs at the level of a direct 
physical interaction (with or without involvement of adapter 
proteins, Figure 2A), if it involves endocytosis (Figure 2B) 
in a complex or if the interaction and cooperation is mainly 
a result of the use of shared downstream signaling elements 
(e.g., TRIF and TRAM, Figure 2C). 
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